Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Google

- PMLiVE

Eli Lilly partners with OpenAI to discover antimicrobials for drug-resistant pathogens

Antimicrobial resistance has been declared by WHO as one of the top ten global public health threats

- PMLiVE

AstraZeneca’s Truqap plus Faslodex granted EC approval to treat advanced breast cancer

More than 550,000 new cases of breast cancer were diagnosed in Europe in 2022

- PMLiVE

Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

The neurodegenerative condition currently affects nearly ten million people worldwide

- PMLiVE

GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers

There are more than 10,000 deaths due to liver disease each year in the UK

- PMLiVE

ICR’s cancer cell study could offer longer-lasting protection for breast cancer patients

The condition affects over 55,000 people in the UK every year

- PMLiVE

Sanofi, Formation Bio and OpenAI announce AI collaboration to accelerate drug development

The companies will combine data, software and tuned models to bring new medicines to patients more efficiently

- PMLiVE

Study reveals new breast cancer genes found in women of African ancestry

More than 240,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

NICE recommends three tumour profiling tests for early breast cancer patients

Breast cancer is the most common cancer in the UK, affecting more than 55,000 people every year

Beyond-AI-Anxiety

Beyond the AI anxiety: The impact of human intuition

Explore the ways we're adapting to work with AI, not against it

Mednet Group

- PMLiVE

New immune cell discovery could lead to personalised breast cancer treatments

The study revealed the key features of immune cells in helping the body’s immune system fight cancer

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study

More than two million cases of breast cancer were diagnosed globally in 2022

- PMLiVE

UK study reveals significantly higher risk of second cancers among breast cancer survivors

Breast cancer is currently the most commonly diagnosed cancer in the UK, affecting around 56,000 people annually

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links